ABUS

Arbutus Biopharma Corporation

ABUS · CIK 1447028 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$6M
20172024
Net Income−$70M
20172024
Operating CF−$65M
20172024
Free Cash Flow−$65M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B$0.1B$0.1B$0.1B
SG&A Expense————————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.38$-0.44$-0.46$-0.83—$-0.46$-0.38$-1.56
EPS (Diluted)$-0.38$-0.44$-0.46$-0.83——$-0.38$-1.56

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.1B$0.2B$0.2B$0.1B$0.1B$0.2B$0.2B
Current Assets$0.1B$0.1B$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B$0.1B
Total Liabilities$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B$0.1B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B$0.2B$0.1B$0.1B$0.2B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.1B$-0.1B$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$0.0B$0.1B$-0.1B$-0.0B$-0.0B$0.0B$-0.0B$0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.1B$0.1B$0.0B$0.1B$0.0B
← Companies